QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Cagrilintide + Semaglutide Blend?
Cagrilintide + Semaglutide Blend (CagriSema — dual amylin+GLP-1 receptor co-agonism) is a Pre-blended cagrilintide + semaglutide (equimolar per vial). Pre-blended combination of cagrilintide (amylin receptor: CALCR+RAMP1/2/3) and semaglutide (GLP-1R). Dual amylin+GLP-1R activation produces additive appetite suppression via complementary brainstem (amylin) and hypothalamic (GLP-1R) circuits. CagriSema Phase 3 (REDEFINE-1, 2025): ~23% mean weight reduction.
Research Applications
Dual Amylin+GLP-1R
CALCR/RAMP + GLP-1R co-activation — complementary appetite circuits
CagriSema Phase 3 Reference
REDEFINE-1 2025 reference compound — 23% weight reduction
Additive Appetite Suppression
Beyond selective GLP-1R agonism — amylin brainstem circuits
vs Tirzepatide
Different dual mechanism: amylin+GLP-1R vs GIP+GLP-1R
Amylin Receptor Biology
CALCR/RAMP complex pharmacology alongside GLP-1R
Quick Specs
| Form | Pre-blended cagrilintide + semaglutide |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not applicable (dual peptide combination) |
| Molecular Formula | Sequence-specific (Cagrilintide + Semaglutide) |
| Peptide Type | Dual Amylin Analog + GLP-1 Receptor Agonist Blend |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |




